Tech Company Financing Transactions
Eikonizo Therapeutics Funding Round
Eikonizo Therapeutics, operating out of Cambridge, secured investment from Novo Nordisk.
Transaction Overview
Company Name
Announced On
12/11/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to consolidate the development of its lead candidate, EKZ-102, and enable the advancement of novel HDAC6 inhibitors.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
245 Main Street, 2nd Floor, CIC Cambridge
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Not Recorded
Overview
We are committed to developing life-changing therapies. Eikonizo's vision is to develop novel, disease-modifying small molecule therapeutics to improve the lives of people impacted by neurodegenerative, cardiorenal and other diseases. Our approach is designed to de-risk and hasten clinical development of therapies that will significantly improve people's lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Steve Tregay
Chief Executive Officer
Rick Lundberg
Chief Operating Officer
Alix Gregory
Chief Scientific Officer
Richard Fisher
VP - Bus. Development
Jim Luterman
VP - Finance
Jon Graves
VP - R & D
Tonya Gilbert
VP - R & D
Al Schroeder
Browse more venture capital transactions:
Prev: 12/11/2024: Kaymbu venture capital transaction
Next: 12/11/2024: Carbogenics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs